The Zhitong Finance App learned that Nomura released a research report saying that maintaining the “buy” rating of Jin Xin Reproduction (01951), considering the recovery in demand and the contribution of newly acquired hospitals, the revenue forecast for the 2023/24 fiscal year was raised by 2%/9%, the net profit forecast increased by 5%/13%, and the target price was raised from HK$8.71 to HK$8.9.

The bank predicts that the Group's operating revenue for FY2022 will increase 25% year on year and net profit will increase 4% year on year. It also estimates that total revenue will increase 25% year on year to 2.29 billion yuan, 7% lower than market expectations of 2.47 billion yuan. This means that the company will receive revenue of 1.16 billion yuan in the second half of the fiscal year, an increase of 18% over the previous year. This is mainly due to the impact on Chengdu and Shenzhen business, especially in the fourth quarter of last year.